Advances in the risk stratification and treatment of essential thrombocythemia

Acute Myelogenous Leukemia AML: Transplant or Not?Подробнее

Novel therapeutics in essential thrombocythemiaПодробнее

Advances in Essential Thrombocythemia ResearchПодробнее

Identifying risk factors for thrombosis in MPNs and treatment strategiesПодробнее

Treatment goals in Essential Thrombocythemia and Polycythemia veraПодробнее

Advances in the science and treatment of MPNsПодробнее

Case 3: Low- to Intermediate- Risk Essential ThrombocythemiaПодробнее

Case 1: Risk Stratification Models for MyelofibrosisПодробнее

Refining the 2022 ELN guidelines for AML risk stratification using machine learningПодробнее

SURPASS ET: P1101 in essential thrombocythemiaПодробнее

SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemiaПодробнее

Essential Thrombocythemia with Dr. Raajit RampalПодробнее

Emerging Therapies in Essential ThrombocytopeniaПодробнее

Current therapy options and clinical outcomes analysis in patients with PVПодробнее

The importance risk stratification to enable risk-adapted therapy in MDS & CMMLПодробнее

Case 3: Prediction of Thrombosis in Essential ThrombocythemiaПодробнее

Essential Thrombocythemia: What Patients Should Know (2022) | Top MPN Specialist Dr. Ruben MesaПодробнее

What Are Treatment Options for Essential Thrombocythemia?Подробнее

Unmet needs and therapeutic strategies in essential thrombocythemiaПодробнее

Exciting updates in essential thrombocythemia: exploring novel agentsПодробнее